← Alle Unternehmen
Über das Unternehmen
Alivion, an ETH Spin-off, develops handheld devices to detect biomarkers in breath to define individual fat-burns rate for personalized weight management. Target market: weight management monitoring for diets (incl. GLP-1), fitness & sports, longevity enhusiasts (market potential > $70bn; double digit growth). Business model (B2B; non-medical): Phase 1: Sales of handheld devices 'Nutrion' through distributor to dieticians & endocrinologists and App subscription for gameification and recommendations (and advertisment income from Freemium App); Phase 2: Sales of 'Neo' device and App Subscription for B2B2C (non-medical) for sports and longevity enhusisasts.